+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo



Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo



Antimicrobial Agents and ChemoTherapy 35(11): 2262-2266



Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine [DHPG], were evaluated for their inhibitory effects on human cytomegalovirus (HCMV) replication in human embryonal fibroblasts and on rat cytomegalovirus (RCMV) replication in rat embryonal fibroblasts. The concentrations of HPMPC or DHPG required to inhibit HCMV plaque formation by 50% were 0.1 and 0.6 micrograms/ml, respectively. For RCMV, these values were 1.1 and 25 micrograms/ml, respectively. For HCMV, the selectivity indices of HPMPC and DHPG, as determined by the ratio of the 50% inhibitory concentration for cell growth to the 50% inhibitory concentration for virus plaque formation, were 1,250 and 140, respectively, and for RCMV, they were 500 and 76, respectively. HPMPC was far more active than DHPG against RCMV infection in vivo as measured by mortality, histopathological changes, and virus titers in organs of immunocompromised RCMV-infected rats. The minimal effective dosage required to prevent mortality from RCMV infection was a single dose of HPMPC at 2 mg/kg of body weight compared with DHPG therapy twice daily at 20 mg/kg/day for 5 days. Furthermore, HPMPC was more effective than DHPG in reducing virus titers in internal organs (P less than 0.01) and in RCMV-induced histopathologic lesions. In contrast to DHPG, which did not show activity when administered 1 day before infection, HPMPC was effective even when administered 7 days before RCMV infection.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039614456

Download citation: RISBibTeXText

PMID: 1666493

DOI: 10.1128/aac.35.11.2262


Related references

Comparative effect of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine treatment on cytomegalovirus-induced interstitial pneumonitis in allogeneic bone marrow transplant recipient rats. Transplantation Proceedings 25(1 Pt 2): 1248-1249, 1993

Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology 179(1): 41-50, 1990

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. European Journal of Clinical Microbiology and Infectious Diseases 12(4): 269-279, 1993

S 1 3 hydroxy 2 phosphonylmethoxypropyl cytosine hpmpc a potent and selective inhibitor of cytomegalovirus infection in vitro and in vivo. Touraine, J L , Et Al (Ed ) Transplantation And Clinical Immunology, Vol Xxiii Virus And Transplantation; Proceedings Of The Twenty-Third International Course, Lyon, France, June 3-5, Xiii+434p Elsevier Science Publishers B V : Amsterdam, Netherlands; (Dist in The Usa And Canada By Elsevier Science Publishing Co , Inc : New York, New York, Usa) Illus 169-176, 1991

Efficacy of s 1 3 hydroxy 2 phosphonylmethoxypropyl cytosine and 9 1 3 dihydroxy 2 propoxymethylguanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. Journal of Medical Virology 37(1): 67-71, 1992

Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Antiviral Research 16(1): 41-52, 1991

Breakthrough of cytomegalovirus infection despite 9-(1,3-dihydroxy-2-propoxymethyl)guanine therapy. Annals of Internal Medicine 104(4): 587, 1986

Cytomegalovirus infection, 9-(1,3-Dihydroxy-2-propoxymethyl)guanine, and Crohn's disease. Annals of Internal Medicine 105(2): 302-303, 1986

Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrobial Agents and ChemoTherapy 24(4): 518-521, 1983

Antiviral effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against cytomegalovirus infection in a guinea pig model. Antiviral Research 7(1): 11-23, 1987

Inhibition of murine cytomegalovirus lung infection and interstitial pneumonitis by acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrobial Agents and ChemoTherapy 28(2): 172-175, 1985

Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Research 13(5): 237-252, 1990

Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system. Antimicrobial Agents and ChemoTherapy 38(10): 2404-2408, 1994

Generalized cytomegalovirus (CMV) infection and CMV-induced pneumonitis in the rat: Combined effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine and specific antibody treatment. Antiviral Research 25(2): 147-160, 1994

Interaction of 9-(1,3-dihydroxy-2-propoxymethyl)guanine with cytosol and mitochondrial deoxyguanosine kinases: possible role in anti-cytomegalovirus activity. Molecular and Cellular Biochemistry 69(1): 75-81, 1985